Table 2.
Associations between the representative SNP in IRAK2 and overall survival of NSCLC patients in PLCO database
| Genotype | Frequency | Univariate analysis | Multivariate analysisa | |||
|---|---|---|---|---|---|---|
|
| ||||||
| All | Death (%) | HR (95%CI) | P | HR (95%CI) | P | |
| IRAK2 | ||||||
| rs779901 C>T | ||||||
| CC | 873 | 595 (68.2) | 1.00 | 1.00 | ||
| CT | 286 | 188 (65.7) | 0.93 (0.79-1.10) | 0.379 | 0.82 (0.70-0.97) | 0.023 |
| TT | 24 | 14 (58.3) | 0.76 (0.45-1.30) | 0.315 | 0.46 (0.26-0.82) | 0.009 |
| CT+TT | 310 | 202 (65.2) | 0.92 (0.78-1.07) | 0.276 | 0.79 (0.67-0.93) | 0.005 |
| Trend | 0.91 (0.79-1.05) | 0.214 | 0.78 (0.68-0.91) | 0.001 | ||
| CC+CT | 1159 | 783 (67.6) | 1.00 | 1.00 | ||
| TT | 24 | 14 (58.3) | 0.78 (0.46-1.32) | 0.347 | 0.49 (0.27-0.87) | 0.015 |
Abbreviations: SNP, single-nucleotide polymorphisms; TLR, toll-like receptor; NSCLC, non-small cell lung cancer; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; HR, hazards ratio; CI, confidence interval.
a
Multivariate Cox regression analyses with adjustment for age, sex, smoking status, histology, tumor stage, chemotherapy, radiotherapy, surgery, PC1, PC2, PC3, and PC4.